Overview
BioPhoenix Co. (BPC), an innovative pharmaceutical company, was established in 2025 through the spin-off of San Fu Biotech, a subsidiary of San Fu Chemical Co. (TWSE: 4755), a publicly listed company in Taiwan. BPC is committed to high-value new drug development by leveraging a professional team and integrating innovative R&D resources. The company focuses on accelerating the launch of novel small molecule drugs (NCEs) that address unmet medical needs in three major global therapeutic areas: ophthalmology, immunology, and oncology. Our mission is to deliver impactful treatment solutions and become a force for societal good through innovation in drug discovery and development.
BioPhoenix is driven by a deep commitment to advancing public health and well-being.
We continually pursue innovation to deliver high-quality products that meet a broad spectrum of medical needs with exceptional value.
Our mission is to become an innovative pharmaceutical company that accelerates meaningful innovation for the benefit of society.
At the heart of our culture are the principles that guide every decision we make: innovation, integrity, and simplicity.
Our Vision
Advancing First-in-Class Therapies Through Global Integration and Artificial Intelligence
